Vendor, Greenville, SC
Neurohope Therapeutics, Inc.
UEI YH1JEE27ME68, CAGE 03W69
2 awards and $1,535,766 obligated between January 31, 2025 and May 26, 2026, 100% under full and open competition, against 22.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $1,535,766 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HT942726CE012Definitive Contract, March 30, 2026, Full and Open Competition After Exclusion of Sources, 3 offers | Defense Health AgencyDefense Health Agency | Dexamethasone Nanotherapeutics for Traumatic Brain InjuryNAICS 541715, PSC AN12 | $1,286,279 |
| HT942525P0023Purchase Order, January 31, 2025, Full and Open Competition After Exclusion of Sources, 42 offers | Army Med Res Acq ActivityDefense Health Agency | DHA SBIR Phase I for Project Titled, "dexamethasone Nanotherapeutics for Traumatic Brain Injury"NAICS 541715, PSC AN12 | $249,487 |
- Places of performance
- South Carolina
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 4 across 2 awards